Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice

FEMS Immunology and Medical Microbiology

Volumn 41, Issue 3, 2004, Pages 249-258

  Khan, Masood A ^a   Nasti, T H ^a   Saima, Khanam ^a,b   Mallick, A I ^a   Firoz, Ahmad ^a   Wajahul, Haq ^a,c   Ahmad, Nadeem ^a,d   Mohammad, Owais ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

^d Central Drug Research Institute ^*

Author keywords

Candidiasis; Immunomodulator; Liposome; Nystatin; Tuftsin

Indexed keywords

AMPHOTERICIN B; IMMUNOMODULATING AGENT; LIPOSOME; NYSTATIN; TUFTSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; FEMALE; FUNGAL STRAIN; IMMUNE SYSTEM; IMMUNOMODULATION; INFECTION SENSITIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; LIPOSOMES; MICE; MICE, INBRED BALB C; NEUTROPENIA; NYSTATIN; TREATMENT OUTCOME; TUFTSIN;

EID: 2942542655     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsim.2004.03.011     Document Type: Article

References (33)

1. Ashman R.B., Gupta J.M. Production and function of cytokines in natural and acquired immunity to C. albicans infection. Microbiol. Rev. 59:1995;646-672
2. Grunig G., Corry D.B., Leach M.W., Seymour B.W.P., Kurup V.P., Rennick D.M. Interlukin-10 is a natural suppresser of cytokine production and inflammation in murine model of allergic bronchopulmonary aspergillosis. J. Exp. Med. 185:1997;1089-1100
3. Murphy J.W., Friedman H., Bendinelli M. Fungal Infections and Immune Responses. 1993;Plenum Press, New York
4. Horn R., Wong B., Kiehn T.E., Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset and results of therapy. Rev. Infect. Dis. 7:1985;646-655
5. Klein R.S., Carol A.H., Small C.B., Moll B., Lesser M., Friedland H. Oral Candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:1984;3540-3588
6. Szabo I., Guan L., Rogers T.J. Modulation of macrophage phagocytic activity by cell wall IL-12 by complement components of C. albicans. Cell. Immunol. 164:1995;182-188
7. Chaffin W.L., Lopez-Ribot J.L., Casanova M., Gozalbo D., Martinez D. Cell wall and secreted proteins of C. albicans: identification, function and expression. Microbiol. Mol. Biol. Rev. 62:1998;130-180
8. Danley D.L., Hilger A.E. Stimulation of oxidative metabolism in murine polymorphonuclear leukocytes by unopsinized fungal cells: evidence for a mannose-receptor specific mechanism. J. Immunol. 127:1981;551-556
9. Kubo S., Rodriguez T. Jr., Roh M.S., Oyedeji C., Romsdahl M.M., Nishioka K. Stimulation of phagocytic activity of murine kupffer cells by tuftsin. Hepatology. 19(4):1994;1044-1049
10. Nishioka K., Wagle J.R., Rodriguez T. Jr., Maeta M., Kubo S., Dessens S.E. Studies of human granulocyte phagocytosis stimulation by tuftsin. J. Surg. Res. 56(1):1994;94-100
11. Chaudhuri M.K., Konopinska D., Bump N.J., Najjar V.A. The similarity between tuftsin (Thr-Lys-Pro-Arg) receptors and tuftsin antibody: a case of induced molecular mimicry. Ann. NY Acad. Sci. 419:1983;135-142
12. Nishioka K. Migration enhancement by tuftsin of human mononuclear cells and its effect on the migration inhibition factor test with tumor antigen. Gann. 69:1978;569-572
13. Agarwal A., Kandpal H., Gupta H.P., Singh N.B., Gupta C.M. Tuftsin bearing liposomes as rifampicin vehicles in the treatment of tuberculosis in mice. Antimicrob. Agents. Chemother. 38:1994;588-593
14. Guru P.Y., Agarwal A.K., Singha U.K., Singhal A., Gupta C.M. Drug targetting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett. 254:1989;204-208
15. Masood A.K., Faisal S.M., Haque W., Owais M. Immunomodulator tuftsin augments antifungal activity of Amp B against experimental murine Candidiasis. J. Drug Target. 10(3):2002;185-192
16. Owais M., Krishnakumar B., Jain B., Bachhawat B.K., Gupta C.M. Tuftsin bearing liposomes as drug vehicles in the treatment of experimental aspergillosis. FEBS Lett. 326:1993;56-58
17. Kirkpatrick C.H. Host factors in defence against fungal infections. Am. J. Med. 77:1984;1-14
18. Mencacci A., Cenci E., Bacci A., Bistoni F., Romani L. Host immune reactivity determines the efficiency of combination immuno therapy and antifungal chemotherapy in candidiasis" J. Infec. Dis. 181(2):2000;686-694
19. Shalit I., Horez-Azaria L., Fabian I., Blau H., Kariv N., Shecht I., Alteraz H., Kletter Y. Immunomodulatory and protective effects of Moxifloxacin against C. albicans - Induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob. Agents Chemother. 46(8):2002;2442-2449
20. Singleton W.S., Gray M.S., Brown M.L. A method for adsorbent fractionation of cottonseed oil for experimental intravenous fat emulsions. J. Am. Oil. Chem. Soc. 42:1965;53-56
21. Gupta C.M., Puri A., Jain R.K., Bali A., Anand N. Protection of mice against Plasmodium berghei infection by a tuftsin derivative. FEBS Lett. 205:1986;351-354
22. Owais M., Gupta C.M. Liposome mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur. J. Biochem. 267:2000;3946-3956
23. Mehta T.R., Hopfer L.R., McQueen T., Juliano R.L., Lopez-Berestein G. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. 31(12):1987;1901-1903
24. Brown B.A. Hematology: Principles and Procedures. third ed. 1980;Lea & Febiger, Philadelphia
25. Lopez-Ribot J.L., Robert K.M., Sofia P., William K.R., Michael R.G., Thomas P.F. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal Candidiasis in human immunodeficiency virus infected patients. Antimicrob. Agents Chemother. 43:1999;1621-1630
26. National Committee for Clinical Laboratory Standards. Reference Method for broth dilution antifungal susceptibility testing for yeasts Approved standard M 27-A. National Committee for Clinical laboratory standards, Villanova, PA, 1995
27. Agrewala J.N., Owais M., Gupta C.M., Mishra G.C. Antigen incorporation into liposomes results in the enhancement of IL-1, IL-4 and Ig G1 secretion: evidence for preferential expansion of Th2 cells. Cytokines Mol. Therapy. 2:1996;59-65
28. Masood A.K., Faisal S.M., Nasti H.T., Saima K., Haq W., Shehbaz A., Owais M. Use of Tuftsin bearing nystatin liposomes against an isolate of C. albicans showing less in vivo susceptibility to amphotericin B. J. Drug Target. 11(2):2003;93-99
29. Kirsh R., Poste G. Liposome targetting to macrophages: Opportunities for treatment of infectious diseases. Adv. Exp. Med. Biol. 202:1986;171-184
30. Siemion I.Z., Kluczyk A. Tuftsin: On the 30-year anniversary of Victor Najjar's discovery. Peptides. 20:1999;645-674
31. Vasquez-Torres A., Jones-Carson J., Balish E. Peroxynitrite contributes to the candidacidal activity of nitric oxide producing macrophages. Infect. Immun. 64(8):1996;3127-3133
32. Cillari E., Arcoleo F., Dieli M., D'Agostino R., Gromo G., Leoni F., Milano S. The macrophage-activating tetrapeptide tuftsin induces nitric oxide synthesis and stimulates murine macrophages to kill Leishmania parasite in vitro. Infect. Immun. 62(6):1994;2649-2652
33. Cheng J.T., Witty R.T., Robinson R.R., Yarger W.E. Amphotericin B nephrotoxicity increased renal resistance and tubule permeability. Kidney Int. 22:1982;626-633